Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | CPS1 | P31327 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757928 | 0.91 | GPR119 (0.44) | GPR119WNT1GSK3BDYRK1ACYP4F2 | |
| SCHEMBL16757932 | 0.91 | GPR119 (0.44) | GPR119WNT1GSK3BDYRK1ACYP4F2 | |
| SCHEMBL18848890 | 0.91 | GPR119 (0.49) | GPR119WNT1GSK3BDYRK1AHCRTR2 | |
| SCHEMBL18848868 | 0.88 | HCRTR2 (0.38) | GPR119HCRTR2HCRTR1 | |
| SCHEMBL18848990 | 0.88 | GPR119 (0.51) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL16769052 | 0.87 | GPR119 (0.51) | GPR119WNT1GSK3BDYRK1ACYP4F2 | |
| SCHEMBL21043272 | 0.86 | GPR119 (0.51) | GPR119CPS1HCRTR2CYP4F2CYP4A11 | |
| SCHEMBL16769045 | 0.86 | GPR119 (0.51) | GPR119CPS1HCRTR2CYP4F2CYP4A11 | |
| SCHEMBL18848863 | 0.86 | GPR119 (0.51) | GPR119CPS1HCRTR2CYP4F2CYP4A11 | |
| SCHEMBL16758097 | 0.86 | GPR119 (0.53) | GPR119WNT1GSK3BDYRK1ACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776987-B2 | Amide derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-10-03 | — | — | US | disclosed |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-11 | — | — | US | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GLP1R | GPR119 1/4885CPS1 2265/4885WNT1 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.